REGENXBIO Inc. (RGNX): Cost of Revenue

Annual figures by period end, from SEC filings.

$33.57M
Year ended 2024-12-31
-13.5%
3-year compound annual growth
+32.4%
5-year compound annual growth
$54.55M2017-12-31: $1.71M2018-12-31: $9.64M2019-12-31: $8.24M2020-12-31: $35.71M2021-12-31: $51.83M2022-12-31: $54.55M2023-12-31: $37.21M2024-12-31: $33.57M$33.57M
2017-12-31 Cost of Revenue (USD) 2024-12-31
Period endedCost of RevenueChange YoYSource filing
2024-12-31$33.57M-9.8%2025-03-13, From 2024-01-01
2023-12-31$37.21M-31.8%2025-03-13, From 2023-01-01
2022-12-31$54.55M+5.2%2025-03-13, From 2022-01-01
2021-12-31$51.83M+45.1%2024-02-27, From 2021-01-01
2020-12-31$35.71M+333.4%2023-02-28, From 2020-01-01
2019-12-31$8.24M-14.5%2022-03-01, From 2019-01-01
2018-12-31$9.64M+464.1%2021-03-01, From 2018-01-01
2017-12-31$1.71Mn/a2020-02-26, From 2017-01-01